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OBJECTIVES We sought to prospectively determine whether patients with congestive heart failure (CHF)
at risk for paroxysmal atrial fibrillation (PAF) could be identified by clinical and study
variables including the P-wave signal-averaged electrocardiogram (P-SAECG).
BACKGROUND Although it is important to assess the risk of developing PAF in patients with CHF, it still
remains difficult to predict the PAF appearance in patients with CHF clinically.
METHODS The study group consisted of 75 patients in sinus rhythm without a history of PAF, whose
left ventricular ejection fraction, as measured by radionuclide angiography, was ,40%. These
patients underwent P-SAECG, echocardiography and 24-h Holter monitoring; in addition,
the plasma concentration of atrial natriuretic peptide (ANP) was measured at study entry.
RESULTS An abnormal P-SAECG was found at study entry in 29 of 75 patients. In the follow-up
period of 21 6 9 months, the PAF attacks documented on the ECG significantly more
frequently occurred in patients with (32%) rather than without an abnormal P-SAECG (2%)
(p 5 0.0002). The plasma ANP level was significantly higher in patients with rather than
without PAF attacks (75 6 41 vs. 54 6 60 pg/ml, p 5 0.01), although there were no
significant differences in age, left atrial dimension or high grade atrial premature beats
between the groups. The multivariate Cox analysis identified that the variables significantly
associated with PAF development were an abnormal P-SAECG (hazard ratio 19.1, p 5
0.0069) and elevated ANP level $60 pg/ml (hazard ratio 8.6, p 5 0.018).
CONCLUSIONS An abnormal P-SAECG and elevated ANP level could be predictors of PAF development in
patients with CHF. (J Am Coll Cardiol 2000;35:405–13) © 2000 by the American College
of Cardiology
Atrial fibrillation (AF) occurs in a variety of clinical settings,
and congestive heart failure (CHF) is one of the established
predisposing conditions for the development of AF (1–3).
Some studies have shown that the onset of AF was
associated with clinical and hemodynamic deterioration and
might predispose to systemic thromboembolism and poorer
prognosis (4,5). The ability to define the risk factors for AF
in patients with CHF would have important clinical rele-
vance. However, it remains unclear which type of patients
with CHF would develop AF.
Recently, other investigators (6–8) and we (9–12) have
used the P-wave signal-averaged electrocardiogram (P-
SAECG) to assess the risk of paroxysmal atrial fibrillation
(PAF) attacks. However, these studies included fewer pa-
tients with impaired cardiac function. In patients with
CHF, the atrial electrophysiologic property might be mod-
ified by hemodynamic overloading (13–15) and neurohu-
moral activation (16,17), which are frequently observed in
CHF. It remains to be clarified whether the appearance of
PAF attacks in patients with CHF would also be predicted
by the P-SAECG. The aim of this study was to determine
prospectively whether patients with CHF at risk for PAF
would be identified by clinical and study variables including
the P-SAECG.
METHODS
Study patients. This study included 104 consecutive out-
patients with stable CHF whose left ventricular ejection
fraction (LVEF), as measured by radionuclide angiography,
was ,40%, and these patients were screened in our heart
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failure unit between September 1995 and November 1997.
Twenty-nine of 104 patients were excluded because 1) the
underlying rhythm was not sinus (chronic AF in 22 pa-
tients); 2) there was a history of PAF documented on the
ECG (three patients were taking a class Ia or Ic antiarrhyth-
mic drug); 3) three patients were taking amiodarone, which
could affect the results of the P-SAECG, because of
sustained ventricular arrhythmia; and 4) one patient did not
give consent to the follow-up period. A total of 75 patients
were enrolled in this study. Each patient gave written,
informed consent to participate in this study, which was
approved by the Review Committee of the Osaka Prefec-
tural General Hospital.
The mean age of the patients was 65 6 11 years (range 34
to 85) at study entry. There were 61 men and 14 women.
Fifty of them (67%) had ischemic heart disease, and the
remaining 25 patients (33%) had nonischemic etiologies.
The average New York Heart Association (NYHA) func-
tional classification was 2.1 6 0.6, with 18% of patients in
class I, 57% in class II and 24% in class III congestive heart
failure. The LVEF was 30 6 6% (range 14% to 39%). The
interval from the onset of CHF symptom, such as exertional
dyspnea, to study entry was 32 6 27 months (range 3 to
108).
Measurements. Before entering this study, patients under-
went radionuclide angiography. At entry, all patients un-
derwent P-SAECG, standard 12-lead ECG, 24-h Holter
monitoring and echocardiography; 6-min walk distance was
also measured. Furthermore, venous blood was sampled for
assay of plasma neurohormones.
RADIONUCLIDE ANGIOGRAPHY. All patients underwent
ECG-gated blood pool scintigraphy at rest in the supine
position using a conventional rotating gamma camera
(Prism 2000, Picker, Bedford, Ohio) equipped with a low
energy, high resolution, parallel-hole collimator. Patients
were given 740 MBq of technetium-99m–labeled human
serum albumin (Nihon Medi-Physics, Nishinomiya, Japan).
The camera was positioned in the modified left anterior
oblique projection to isolate the left ventricle from other
cardiac structures, and data acquisition was then performed.
Then, LVEF was calculated using the standard program
(18).
P-WAVE SIGNAL-AVERAGED ELECTROCARDIOGRAPHY.
The methodology of P-SAECG recording and analysis has
been described previously (9–11). The P-SAECG was
recorded from a modified X, Y and Z lead system using the
VCM-3000 (Fukuda Denshi, Ltd., Tokyo, Japan). All of
the digital data were stored on a floppy disk. The standard
lead I was used as the X lead. Lead aVF was used as the Y
lead. Similarly, the precordial lead V1 was used as the Z
lead. The signal from each lead was amplified up to 5
mV/cm and passed through a low bandpass filter of 300 Hz
(the slope; 12 dB/octave) and a high bandpass filter of
40 Hz (the slope; 18 dB/octave), and then converted from
analog-to-digital data to a 12-bit accuracy at the sampling
rate of 1 kHz. A specially filtered P wave derived from the
selected dominant sinus P wave of lead II or V1 served as a
reference signal for all processing. After passing through a
P-wave recognition program to eliminate ectopic atrial
beats, signals .200 beats were averaged on a trigger point
within the specially filtered P wave. If the noise level
remained .1 mV, even after 200 beats averaging, the
averaging was continued until the peak noise level was
reduced to ,1 mV. The filtered signals for the X, Y and Z
leads were combined into a spatial magnitude: (X2 1 Y2 1
Z2)1/2. The onset and offset of the filtered P wave were
defined as signals during the interval when signals showed a
persistent level of 1 mV. The duration (Ad) and the
root-mean-square voltage for the last 20 ms (LP20) of the
signal-averaged P wave were measured in the vector mag-
nitude. Percent variation (day to day) of Ad and LP20 in
patients with CHF were 1.3 6 0.4% and 8.8 6 4.3% (n 5
32), respectively.
An abnormal P-SAECG was defined as Ad .132 ms
and LP20 ,2.3 mV, each of which was the 90th percentile
value obtained from 132 normal control subjects (66 men
and 66 women, average age 38 6 17 years [range 14 to 80])
who had neither clinical symptoms nor signs suggestive of
organic heart disease on chest radiography or standard
ECG. The Ad and LP20 were 118 6 10 ms and 3.2 6 0.9
mV, respectively. An abnormal P-SAECG was observed in
only 3 (2.3%) of the 132 normal control subjects.
STANDARD ELECTROCARDIOGRAPHY. The P-wave dura-
tion and the PR interval were measured in lead II of the
scalar ECG recorded at a chart speed of 200 mm/s, and the
presence of P mitrale (left atrial enlargement) was also
examined in lead V1 (a negative P wave of 0.04 s in duration
and 0.1 mV in depth).
HOLTER MONITORING. Twenty-four-hour dual-channel
Holter ECG recordings were obtained with a Marquette
Electronics (Milwaukee, Wisconsin) 8000 Holter monitor-
ing system. Holter data were evaluated by the number and
characteristics of atrial premature beats (APBs), graded into
the following five categories: no APBs; ,10 APBs/h; 10 to
Abbreviations and Acronyms
Ad 5 duration of signal-averaged P wave
AF 5 atrial fibrillation
ANP 5 atrial natriuretic peptide
APB 5 atrial premature beat
CHF 5 congestive heart failure
LAD 5 left atrial dimension
LP20 5 root-mean-square voltage for the last
20 ms of signal-averaged P wave
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
PAF 5 paroxysmal atrial fibrillation
P-SAECG 5 signal-averaged electrocardiogram
406 Yamada et al. JACC Vol. 35, No. 2, 2000
Prediction of PAF in CHF by P-SAECG February 2000:405–13
100 APBs/h; .100 APBs/h; and couplets or more of APBs.
The presence of the last two categories of APB was
considered as high grade atrial ectopic activity.
ECHOCARDIOGRAPHY. Two-dimensional echocardiogra-
phy was performed with a Toshiba SSH-160A recorder
equipped with 2.5- or 3.75-MHz transducers. The standard
technique was employed for sizing the left ventricle and
atrium (19). Left ventricular dimension was measured at
end-diastole on the R wave of the ECG-derived QRS
complex just below the level of the mitral leaflets through
the standard left parasternal window. Left atrial dimension
(LAD) was measured as the distance from the leading edge
of the posterior aortic wall to the leading edge of the
posterior left atrial wall at end-systole. Mitral and tricuspid
valve regurgitations were diagnosed by color Doppler echo-
cardiography and quantified using a 41 grading system.
Mitral diastolic flow velocity was assessed by pulsed Dopp-
ler echocardiography from the apical four-chamber view by
positioning the sample volume between the leaflets at the
level of their tips in diastole. The ratio of maximal late to
early diastolic velocities was also measured and averaged
from five consecutive cycles.
HORMONE ANALYSIS. Blood sampling for plasma neuro-
hormone determination was done from an intravenous
cannula after the patient had rested for at least 30 min in the
supine position. The plasma concentration of atrial natri-
uretic peptide (ANP) (20) and aldosterone, as well as
plasma renin activity, was measured in EDTA-plasma by a
radioimmunoassay technique, and the plasma norepineph-
rine concentration was also determined in EDTA-plasma
by high performance liquid chromatography (21) at
Shionogi Biomedical Laboratories (Osaka, Japan). Intra-
assay and interassay coefficients of variation of ANP were
4.7% and 5.8%, respectively.
Follow-up. All patients were followed up every two weeks
for the initial eight weeks and every four weeks thereafter,
and examined by standard ECG or portable ECG moni-
toring to observe the cardiac rhythm. Furthermore, 24-h
Holter monitoring and echocardiography were repeated two
and six months after study entry and every six months
thereafter. The primary physicians taking care of the pa-
tients had no knowledge of the results of P-SAECG or
other measurements.
The development of PAF was the primary end point in
the present study. Paroxysmal atrial fibrillation was defined
as an arrhythmia of supraventricular origin associated with a
grossly irregular ventricular rhythm and no visible P or
flutter waves that lasted for .1 min and did not persist for
6 months. Chronic AF was defined as AF sustained for .6
months. The development of PAF was considered second-
ary in the present study if LAD at study entry was .44 mm
(mean 6 2 SD of normal control subjects) or there was a
gradual increase in LAD without improvement in cardiac
function during the follow-up period.
Statistical analysis. Data are presented as the mean
value 6 SD. The Mann-Whitney U test and the Fisher
exact test were used to compare differences of continuous
and discrete variables, respectively, in patients with and
without an abnormal P-SAECG. The event (PAF)-free
rates in patients with and without an abnormal P-SAECG
were calculated using the Kaplan-Meier method, and the
difference between them was detected using the log-rank
test.
The Mann-Whitney U test and the Fisher exact test were
also used to compare differences in patients with and
without PAF development. Variables for which a difference
(p , 0.1) was observed between the two groups were
analyzed in the univariate Cox proportional hazard model,
and variables such as age, LAD and ANF were dichoto-
mized to make the hazard ratio maximal. The determina-
tion of prognostic significance of an abnormal P-SAECG,
Holter reading, echocardiogram and plasma neurohormone
level was explored by the multivariate Cox proportional
hazards regression model analysis. McNemar’s test was used
to compare sensitivity, specificity and predictive accuracy
among the different criteria for prediction of PAF develop-
ment, and the Fisher exact test was used for comparing
positive and negative predictive values among them.
All statistical analyses except for McNemar’s test were
carried out using the Stat-View statistical package, version
4.5. A p value ,0.05 was considered statistically significant.
RESULTS
Clinical and study characteristics of patients with and
without an abnormal P-SAECG. Seventy-five patients
were dichotomized at study entry on the basis of abnormal
P-SAECG criteria. Twenty-nine patients (group I) had an
abnormal P-SAECG, whereas the other 46 patients did not
(group II). Figure 1 shows the representative tracings of the
P-SAECG in groups I and II. The Ad and LP20 were
Figure 1. Representative tracings of P-SAE (P-SAECG) in a
patient who developed PAF (left, group I) and a patient who did
not develop PAF (right, group II) during the follow-up period.
Note that the signal-averaged P-wave duration is longer and the
terminal portion of the signal-averaged P wave is lower in the
group I patients than in the group II patients. The abnormality of
the P-SAECG was Ad .132 ms and LP20 ,2.3 mV (positive in
group I; negative in group II).
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143.7 6 8.1 ms and 1.82 6 0.3 mV in group I and 135 6
12 ms and 3.28 6 1.32 mV in group II, respectively. There
were no significant differences in age, gender, use of the
class Ib antiarrhythmic agent mexiletine, LVEF, the pres-
ence of high grade APB, LAD and plasma concentration of
neurohormonal factors between groups I and II (Table 1).
Prediction of PAF attacks by the P-SAECG. In the
follow-up period of 21 6 9 months, 10 of the 75 study
patients developed PAF, which was documented by 24-h
Holter monitoring in the outpatient clinical setting (n 5 8)
and at hospital admission for CHF deterioration (n 5 2).
The development of PAF was considered secondary in 5 of
the 10 patients. Five patients experienced palpitation, 2
dyspnea, 1 chest pain and 1 light-headedness associated
with PAF attacks, and 1 patient was asymptomatic. In the
2 patients who were hospitalized for CHF deterioration at
the first development of PAF, sinus rhythm was restored by
electrical cardioversion, whereas the rhythm was spontane-
ously restored to sinus rhythm in the remaining 8 patients.
The transition to chronic AF was subsequently observed in
one of the 2 patients hospitalized for CHF deterioration.
Nine (31%) of the 29 patients in group I developed PAF,
whereas the development of PAF attacks was observed in
only 1 (2%) of the 46 patients in group II. Figure 2 shows
the event (PAF)-free rate curve according to Kaplan-Meier
analysis. Attacks of PAF significantly more frequently
occurred in group I than in group II (p 5 0.0002).
Accordingly, an abnormal P-SAECG gave a sensitivity of
90%, specificity of 69%, positive predictive value of 31% and
negative predictive value of 98% for the prediction of the
development of PAF in patients with CHF.
Comparison between patients with and those without
development of PAF. The clinical and study characteris-
tics of patients with and without PAF development are
shown in Table 2. Patients with PAF attacks (PAF group)
tended to be older (p 5 0.07) than those without PAF
attacks (non-PAF group), although there were no signifi-
cant differences in gender, the presence of ischemic heart
disease, diabetes mellitus or hypertension, the use of a class
Ib antiarrhythmic agent, beta-blocker or angiotensin-
converting enzyme inhibitor, NYHA functional class or
LVEF between them. The Ad was significantly longer (p 5
0.005) and LP20 was lower (p 5 0.02) in the PAF group
than in the non-PAF group (Fig. 3). So, the incidence of an
abnormal P-SAECG was significantly greater (p 5 0.001)
in the PAF group than in the non-PAF group. By Holter
monitoring, high grade APB tended to be observed more
frequently in the PAF group than in the non-PAF group
(p 5 0.07). Echocardiographically, LAD tended to be larger
in the PAF group than in the non-PAF group (p 5 0.09),
although no difference was observed in left ventricular
end-diastolic dimension between the two groups.
Figure 2. PAF-free rate curves according to Kaplan-Meier anal-
ysis in patients with and without an abnormal P-SAE (P-
SAECG) (Ad .132 ms and LP20 ,2.3 mV). The bold line (29
patients with the abnormality) and the narrow line (46 patients
without the abnormality) show the PAF-free rates. The numbers
at the bottom are the number of patients in each group at risk for
the event (PAF attack) at study entry and after each 100-day
period. The PAF-free rate was significantly lower in patients with
rather than without an abnormal P-SAECG.
Table 1. Clinical and Study Characteristics in Patients With
and Without an Abnormality of P-SAECG
With
Abnormality
(n 5 29)
Without
Abnormality
(n 5 46)
p
Value
Clinical characteristics
Age (yrs) 66 6 13 65 6 10 NS
Gender (male) 26 (90%) 35 (75%) NS
Ischemic heart disease 20 (69%) 30 (65%) NS
Diabetes mellius 6 (21%) 8 (18%) NS
Hypertension 1 (3%) 7 (14%) NS
Class Ib antiarrhythmic
drugs
10 (34%) 9 (20%) NS
NYHA functional class 2.1 6 0.7 2.0 6 0.6 NS
6-Min walk distance (m) 358 6 69 383 6 70 NS
Heart rate (beats/min) 76 6 12 74 6 14 NS
Systolic pressure
(mm Hg)
124 6 13 133 6 20 NS
Diastolic pressure
(mm Hg)
73 6 10 76 6 11 NS
Radionuclide angiography
LVEF (%) 30 6 8 30 6 7 NS
Holter monitoring
High grade APB (%) 9 (31%) 14 (30%) NS
Echocardiography NS
LVDd (mm) 60 6 6 61 6 7 NS
LAD (mm) 39 6 8 40 6 6 NS
Neurohumoral pattern
Atrial natriuretic
peptide (pg/ml)
53 6 46 59 6 66 NS
Norepinephrine (pg/ml) 406 6 228 392 6 207 NS
Aldosterone (pg/ml) 71 6 57 87 6 101 NS
Renin (ng/ml per h) 6.6 6 6.9 5.8 6 6.5 NS
Data are presented as the number (%) of patients or mean value 6 SD.
APB 5 atrial premature beats; LAD 5 left atrial dimension; LVDd 5 left
ventricular end-diastolic dimension; LVEF 5 left ventricular ejection fraction;
NYHA 5 New York Heart Association. P-SAECG 5 P wave signal-averaged ECG.
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In the neurohumoral pattern (Fig. 4), ANP concentration
was significantly higher (p 5 0.01) in the PAF group than
in the non-PAF group, although there were no significant
differences in plasma level of norepinephrine, renin or
aldosterone. Figure 5 shows the event (PAF)-free rate curve
according to Kaplan-Meier analysis. The development of
PAF was significantly more frequently observed in patients
with than without an elevated ANP level ($60 pg/ml) (32%
[8/25] vs. 4% [2/50], p 5 0.001).
Predictors of the development of PAF in patients with
CHF. The Cox proportional hazard model analysis was
used to determine the prognostic power of age, the abnor-
mality of P-SAECG, the presence of high grade APB,
LAD and plasma level of ANP. Table 3 shows the results of
univariate and multivariate Cox proportional hazard model
analyses for the prediction of PAF development. By univar-
iate analysis, an abnormal P-SAECG, an elevated ANP
level ($60 pg/ml) and the presence of high grade APB were
significantly related to PAF development. By multivariate
analysis, an abnormal P-SAECG and an elevated ANP level
Figure 3. Plots of Ad and LP20 in patients with and without the
development of PAF. The Ad was significantly longer and the
LP20 was smaller in patients with rather than without the
development of PAF.
Figure 4. Plots of neurohumoral pattern in patients with and
without the development of PAF. The ANP concentration was
significantly higher in patients with rather than without the
development of PAF, although there were no differences in the
plasma level of norepinephrine, aldosterone or renin between the
groups.
Table 2. Clinical and Study Characteristics of Patients With
and Without the Development of PAF
PAF (1)
(n 5 10)
PAF (2)
(n 5 65)
p
Value
Clinical characteristics
Age (yr) 71 6 6 64 6 11 0.07
Gender (male) 8 (80%) 53 (82%) NS
Ischemic heart disease 9 (90%) 41 (63%) NS
Diabetes mellius 3 (30%) 12 (18%) NS
Hypertension 0 (0%) 8 (12%) NS
Class Ib antiarrhythmic
drugs
5 (50%) 14 (22%) NS
ACE inhibitors 5 (50%) 45 (70%) NS
Beta-blockers 2 (20%) 16 (32%) NS
NYHA functional class 2.1 6 0.9 2 6 0.6 NS
6-Min walk distance (m) 342 6 79 379 6 68 NS
Heart rate (beats/min) 72 6 12 75 6 13 NS
Radionuclide angiography
LVEF (%) 30 6 8 30 6 7 NS
P-SAECG
Abnormality 9 (90%) 20 (31%) 0.001
Ad (ms) 147 6 8 137 6 11 0.005
LP20 (mV) 1.9 6 0.2 2.8 6 1.3 0.02
Standard ECG
P-wave duration (ms) 119 6 10 114 6 11 NS
PR interval (ms) 182 6 30 171 6 30 NS
P mitrale 7 (70%) 34 (52%) NS
Holter monitoring
High grade APB (%) 6 (60%) 17 (26%) 0.07
Echocardiography NS
LVDd (mm) 61 6 5 61 6 7 NS
LAD (mm) 43 6 7 39 6 6 0.09
MR (4-grade score) 1.2 6 0.7 1.0 6 0.8 NS
TR (4-grade score) 0.3 6 0.5 0.4 6 0.6 NS
A/E ratio 1.31 6 0.47 1.61 6 0.56 NS
Neurohumoral pattern
Atrial natriuretic peptide
(pg/ml)
75 6 41 54 6 60 0.01
Norepinephrine (pg/ml) 357 6 157 403 6 221 NS
Aldosterone (pg/ml) 79 6 78 81 6 88 NS
Renin (ng/ml per h) 7.5 6 8.2 5.9 6 6.4 NS
Data are presented as the mean value 6 SD or number (%) of patients.
A/E 5 ratio of late to early mitral diastolic velocities; ACE 5 angiotensin-
converting enzyme; PAF 5 paroxysmal atrial fibrillation; MR 5 mitral regurgitation;
TR 5 tricuspid regurgitation. Other abbreviations as in Table 1.
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were independently related to PAF development. The
combination of abnormal P-SAECG and an elevated ANP
level gave a sensitivity of 70%, specificity of 94%, positive
predictive value of 64% and negative predictive value of 94%
for the identification of patients at risk for PAF develop-
ment (Table 4). Predictive accuracy (91%) for the combi-
nation significantly increased (p , 0.01), as compared with
that for abnormal P-SAECG (72%) or elevated ANP level
alone (75%).
Prognostic significance of the development of PAF. In
the present study, 6 of 10 patients who developed PAF
subsequently experienced major events (four hospital admis-
sions for CHF deterioration, one sudden death and one
brain embolism), whereas major events were observed in 9
of 65 patients without PAF development (four hospital
admissions for CHF deterioration and five sudden deaths).
Although there was no significant difference in mortality
between patients with and those without PAF development,
major events were significantly more frequently observed in
patients with rather than without the development of PAF
(60% vs. 14%, p , 0.01).
DISCUSSION
A number of electrophysiologic factors play a role in the
development of AF (22). Atrial fibrillation is generally
believed to result from multiple microreentry (23). Like all
other reentrant arrhythmias, one of these factors in AF is a
depressed atrial conduction. It was reported that the elec-
trophysiologic abnormality of the atrial muscle in patients
with PAF could be detected by P-SAECG (6,7,9,10,12),
and prospective studies showed that P-SAECG would be
useful for the prediction of PAF occurrence after cardiac
surgery (8) and the transition to chronic AF in patients with
PAF (11). However, in previous studies, the study groups
mainly consisted of patients with relatively preserved cardiac
function. In patients with CHF, which is one of the most
frequent precursors of AF, the atrial electrophysiologic
property might be modified by hemodynamic overloading
(13–15) and neurohumoral activation (16,17), which are
frequently observed in CHF. There have been no investi-
gations to determine whether P-SAECG could be used to
assess the risk of PAF in patients with CHF. This prospec-
tive study demonstrated that an abnormal P-SAECG could
define a high risk group of patients with CHF who may
develop PAF, and that the combination of an abnormal
P-SAECG and an elevated ANP level would identify the
higher risk subset for the development of PAF in patients
with CHF.
P-SAECG in patients with CHF. In the present study,
patients with CHF who developed PAF had a significantly
longer Ad than those without PAF. Furthermore, Ad in
patients with CHF who did not develop PAF was also
longer, as compared with that in control subjects. A recent
study showed that Ad in patients with CHF would depend
more on the level of left atrial pressure rather than on LAD
(15). In the present study, Ad significantly correlated with
left ventricular end-diastolic pressure (r 5 0.32, p , 0.05
[n 5 40]) but not with LAD. We think that Ad in patients
with CHF may be determined by hemodynamic overload,
in addition to the electrophysiologic substrate characterized
Figure 5. The PAF-free rate curves according to Kaplan-Meier
analysis in patients with and without an elevated ANP level. The
bold line (25 patients with an elevated ANP level $60 pg/ml) and
the narrow line (50 patients without an elevated ANP level) show
the PAF-free rate. The numbers at the bottom are the number of
patients in each group at risk for the event (PAF attack) at study
entry and after each 100-day period. The PAF-free rate was
significantly lower in patients with rather than without an elevated
ANP level.
Table 3. Univariate and Multivariate Cox Proportional Hazard Analysis for the Identification of
Patients at Risk for PAF
Univariate Analysis Multivariate Analysis
p
Value
Hazard Ratio
(95% CI)
p
Value
Hazard Ratio
(95% CI)
Abnormal P-SAECG 0.0071 17.6 (2.2–135.8) 0.0069 19.1 (2.3–162.3)
ANP $60 pg/ml 0.064 8.6 (1.8–40.7) 0.018 8.6 (1.8–50.9)
High grade APB 0.04 3.7 (1.0–13.2) 0.89 1.1 (0.2–6.3)
Age .66 years 0.05 4.7 (0.99–22.0) 0.48 2.0 (0.3–13.2)
LAD .41 mm 0.06 3.6 (0.94–14.1) 0.11 3.3 (0.8–14.7)
ANP 5 atrial natriuretic peptide; high grade APB 5 .100 APBs/h or couplets or more of atrial premature beats (APBs); CI 5
confidence interval. Other abbreviations as in Table 1.
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by slow inhomogeneous conduction of atrial impulse (24–
26). This consideration is also supported by the experimen-
tal findings that the atrial stretch induced by increased
cardiac loading due to heart failure produced profibrillatory
changes in atrial conduction (13).
Prediction of the development of AF in patients with
CHF. It was reported that the onset of AF in patients with
CHF was associated with clinical and hemodynamic dete-
rioration and might predispose to systemic thromboembo-
lism and poorer prognosis (5). Furthermore, Middlekauf et
al. (4) showed that AF in patients with CHF, whether
paroxysmal or chronic, would be a marker for increased risk
of death. In the present study, patients with PAF develop-
ment experienced major events (hospital admission for
CHF deterioration, sudden death and brain embolism)
more frequently than those without PAF development,
although there was no significant difference in mortality
between them. Therefore, patients with CHF at risk for
PAF should be monitored more frequently and should
possibly have a more aggressive approach to the treatment of
heart failure and thromboembolism.
The Framingham study reported that CHF was the most
powerful independent precursor of AF, with a relative risk
of approximately sixfold (1,3). It has also been shown that
CHF increased the likelihood of recurrence of AF after
electrocardioversion to sinus rhythm (27). Thus, the asso-
ciation between CHF and AF is well documented. How-
ever, the factors that predispose to PAF development have
not been elucidated in patients with CHF. In this study, we
demonstrated that an abnormal P-SAECG and an elevated
ANP level at study entry would be useful predictors of the
development of PAF in patients with CHF. Pozzoli et al.
(5) reported that the occurrence of AF in patients with
CHF could not be predicted by any baseline variable. In
their study, the duration of the P wave was measured from
the standard 12-lead ECG, but ANP was not measured.
The difference between these two studies would be due to
methodologic problems. In contrast, in the present study,
there were no significant differences in age, LAD or the
presence of diabetes mellitus or hypertension between pa-
tients with and those without the development of PAF. The
result suggests that such risk factors of AF in the general
population reported in the Framingham study (3) might not
be predictive of the development of AF in patients with
CHF.
ANP and the development of AF in patients with CHF.
An increased level of ANP has been associated with a poor
prognosis in patients with CHF (28,29). In some studies
(30,31), the influence of chronic AF on the ANP level has
been investigated in patients with CHF, and it was reported
that ANP was further elevated in patients with CHF and
chronic AF, as compared with those in sinus rhythm. The
ANP itself might modulate the atrial electrophysiologic
properties, because it was reported that ANP infusion
shortened the atrial effective refractory period (32). How-
ever, no information has been available on the relation
between ANP and the development of AF in patients with
CHF. In the present study, plasma ANP level was signifi-
cantly higher in patients with CHF with rather than
without PAF development, and elevated ANP level was a
risk factor for PAF development independently of an
abnormal P-SAECG. The results suggest that ANP might
provide prognostic information on the development of PAF
in patients with CHF.
High levels of ANP have been reported in patients with
increased atrial pressure associated with CHF (33). The
main stimulus of release of ANP prohormone from the
atrium is atrial wall stress. We speculate that the relation
between high ANP level and AF development in patients
with CHF might be indirectly brought about by left atrial
wall stress and that the development of AF might not be a
direct result of a high ANP level. Increased atrial pressure in
patients with CHF induces higher wall stress, which not
only stimulates the secretion of ANP from atrial myocytes
but may also produce profibrillatory changes in atrial elec-
trophysiologic properties by stretching the atrial wall. This
speculation is supported by the following data in the present
study. In patients with an elevated ANP level or an
abnormal P-SAECG, improvement in cardiac function
with an increase in LVEF measured by radionuclide an-
giography .5% one year after study entry was observed in
19 patients (ejection fraction 30 6 6% to 44 6 10%). In
these patients, left ventricular end-diastolic dimension
(61 6 7 to 57 6 6 mm, p 5 0.02) and LAD (42 6 5 to
Table 4. Prediction of the Development of Paroxysmal Atrial Fibrillation by an Abnormal P-
SAECG Elevated ANP Level and a Combination of the Two
Abnormal
P-SAECG
Elevated
ANP
Abnormal
P-SAECG and
Elevated ANP
Sensitivity 90% (9/10) 80% (8/10) 70% (7/10)
Specificity 69% (45/65) 74% (48/65) 94%* (61/65)
Positive predictive value 31% (9/29) 32% (8/25) 64% (7/11)
Negative predictive value 98% (45/46) 96% (48/50) 94% (61/64)
Predictive accuracy 72% (54/75) 75% (56/75) 91%† (68/75)
*p , 0.001. †p , 0.01 vs. abnormal P-SAECG or elevated ANP. The numbers in parentheses are the number of patients.
Abbreviations as in Table 3.
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39 6 5 mm, p 5 0.01) significantly decreased one year after
study entry, which might result in the decrease in wall stress.
The decreases in ANP level (52 6 50 to 26 6 20 pg/ml, p 5
0.02) and signal-averaged P-wave duration (143 6 7 to
140 6 7 ms, p 5 0.03) were also observed one year after
study entry in these patients. These data suggest that in
patients with CHF who were then effectively treated, an
elevated ANP level or an abnormal P-SAECG might be
related to wall stress, taking a corresponding improvement
in ANP level and P-SAECG with a decrease in wall stress
into consideration.
Study limitations. First, although patients were carefully
followed up, it could not be ruled out that some patients
with PAF might remain undocumented if their attack was
brief or not so severe. Second, in this study, we studied only
consecutive stable outpatients who had mild to moderate
CHF. The results of our study should not be generalized to
inpatients with severe CHF. Further study is needed to
address this issue. Third, the positive predictive value of an
abnormal P-SAECG was still low (32%), although the
positive predictive value was increased (63%) by combina-
tion of an abnormal P-SAECG and elevated ANP level.
Further prospective study is needed to verify the prognostic
value of ANP as a predictor of AF development in patients
with CHF, as ANP critical level was determined retrospec-
tively in this study.
Conclusions. We concluded that an abnormal P-SAECG
could be a predictor of PAF development in patients with
CHF and that the combination of an abnormal P-SAECG
and an elevated ANP level might identify the higher risk
subset for PAF development in patients with CHF.
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